Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation

Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation

The molecule “T cell immunoreceptor with immunoglobulin and ITIM domain,” or TIGIT, has recently received much attention as a promising target in the treatment of various malignancies. In spite of the quick progression of anti-TIGIT antibodies into clinical testing both as monotherapy and in combina...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Jin-Hwan Han, Mingmei Cai, Jeffery Grein, Samanthi Perera, Hongmei Wang, Mike Bigler, Roenna Ueda, Thomas W. Rosahl, Elaine Pinheiro, Drake LaFace, Wolfgang Seghezzi, Sybil M. Genther Williams
Formáid: Alt
Teanga:English
Foilsithe / Cruthaithe: Frontiers Media S.A. 2020-10-01
Sraith:Frontiers in Immunology
Ábhair:
TIGIT
FcγR
myeloid cells
combination cancer immunotherapy
costimulatory molecules
immune checkpoint blockade
Rochtain ar líne:https://www.frontiersin.org/article/10.3389/fimmu.2020.573405/full

Ar líne

https://www.frontiersin.org/article/10.3389/fimmu.2020.573405/full

Míreanna comhchosúla